Navigation Links
Newer, more intense chemotherapy with less radiation not more effective against Hodgkin's lymphoma
Date:10/25/2010

A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease, according to a first-of-its-kind randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

In addition, the trial showed that a more intensive chemotherapy (BEACOPP) is not more effective than the standard chemotherapy treatment (ABVD) for these patients.

"This confirms that four cycles of ABVD, followed by 30 Gy involved field radiation therapy, should continue to be the standard treatment for early intermediate-stage Hodgkin's lymphoma patients," Hans Theodor Eich, M.D., Ph.D. lead author of the study and a radiation oncologist at the University of Cologne, in Cologne, Germany, said. "Prior to the study, it was unclear what the optimal chemotherapy regimen and the most effective dose of radiation was."

Chemotherapy followed by radiation treatment is the standard treatment for intermediate-stage Hodgkin's lymphoma. This group of patients has the disease in one or more lymph nodes on the same side of the diaphragm (the muscle under the lungs), along with other factors associated with a higher risk of the cancer spreading to other parts of the body.

Fortunately, cure rates among these Hodgkin's lymphomas, even those considered "unfavorable" as studied here, is very high. That is why doctors continue to experiment with treatment to maximize the chances for a cure while limiting the risks of long-term side effects.

This randomized study sought to determine the most effective dose of radiation for some Hodgkin's lymphoma patients. Researchers also examined whether a more intensive form of chemotherapy would improve the risk of cancer spreading, compared to the standard chemotherapy regime.

Between 1998 and 2003, 1,395 patients with untreated, early unfavorable Hodgkin's lymphoma were randomized into one of four treatment arms: the standard chemotherapy regime and radiation dose, the standard chemotherapy with a lower radiation dose, a more intensive chemotherapy regime with the standard radiation dose and the more intensive chemotherapy with a lower radiation dose.

Results of the study confirm that the standard chemotherapy, ABVD, used with the standard dose of radiation therapy, is the best treatment for patients with early, intermediate-stage Hodgkin's lymphoma. Findings also show that a more intensive chemotherapy, BEACOPP, is not more effective than the standard chemotherapy in treating this group of patients.


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Healthier cafeteria food, more intense gym classes lower students diabetes risk
2. Non-intense physical activity to reduce depression and boost recovery of stroke patients
3. "How Facebook Makes Lonely People Even Lonelier" Revealed by Distinguished University of Chicago Professor in Interview with Brian Vaszily on IntenseExperiences.com
4. Intense Cholesterol, Blood Pressure Therapies Dont Help Type 2 Diabetics
5. Chemotherapy plus radiation prevents bladder cancer recurrences
6. Girls with ovarian germ-cell tumors can safely skip chemotherapy unless disease recurs
7. Women fight the effects of chemotherapy long after treatment ends
8. New lung cancer research finds half of advanced lung cancer patients receive chemotherapy
9. IU researchers: Chemotherapy alters brain tissue in breast cancer patients
10. Lung cancer survival rates improved through use of individualized chemotherapy
11. Ancient Chinese medicine may help chemotherapy patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... The California State ... convening academic faculty engaged in or interested in palliative care education and research. The ... be held in North County San Diego on Sept. 28 and 29, 2017, on ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The ... for excellence in radiology marketing programs at the annual Building Better Radiology Marketing ... Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given out in ...
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... ... for qualifying into the Senior International Elite division on February 12th. Ms. ... Around divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida ...
(Date:2/23/2017)... ... 2017 , ... Thinksport, the most award-winning sunscreen on the ... Marin. For the second year in a row, cyclists will stay protected from ... thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts again ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis ... the global Fibromyalgia market. The research answers the following ... for Fibromyalgia and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... PUNE, India , February 23, 2017 ... "Diagnostic Imaging Market by Product (X-ray Imaging Digital, Analog), ... PET)), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, ... MarketsandMarkets, the report studies the global market over the ... expected to reach ~USD 36.43 Billion by 2021, at ...
Breaking Medicine Technology: